| Dr Michael J Oros, MD | |
|
9701 Cleveland Ave Nw Ste 150, North Canton, OH 44720 | |
| (330) 913-7109 | |
| (330) 913-7192 |
| Full Name | Dr Michael J Oros |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 20 Years |
| Location | 9701 Cleveland Ave Nw Ste 150, North Canton, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720278914 | NPI | - | NPPES |
| 0054335 | Medicaid | OH | |
| 0398926 | Medicaid | OH | |
| 0053067 | Medicaid | OH | |
| 36D2080652 | Other | OH | CLIA |
| Entity Name | State Of Ohio Office Of Budget And Management State Accounting |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023082716 PECOS PAC ID: 0143133181 Enrollment ID: O20031202000209 |
News Archive
Obesity increases the risk of developing 10 of the most common cancers, regardless of how it is measured, according to a study of more than 400,000 adults in the UK, being presented at The European Congress on Obesity (ECO) held online this year, with central fatness (larger waist and hips) and general obesity (body mass index [BMI] and body fat percentage) associated with similar estimates of cancer risk.
Kaiser Health News staff writers Mary Agnes Carey and Julie Appleby talk with KFF's Jackie Judd about recent health policy developments, including the newly released Health and Human Services regulations dealing with the medical loss ratio and the status in Congress of the one-month patch to prevent physicians who see Medicare patients from having their payments reduced.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.
› Verified 4 days ago
| Entity Name | Greenbrook Tms Cleveland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417420456 PECOS PAC ID: 8921340415 Enrollment ID: O20190502002017 |
News Archive
Obesity increases the risk of developing 10 of the most common cancers, regardless of how it is measured, according to a study of more than 400,000 adults in the UK, being presented at The European Congress on Obesity (ECO) held online this year, with central fatness (larger waist and hips) and general obesity (body mass index [BMI] and body fat percentage) associated with similar estimates of cancer risk.
Kaiser Health News staff writers Mary Agnes Carey and Julie Appleby talk with KFF's Jackie Judd about recent health policy developments, including the newly released Health and Human Services regulations dealing with the medical loss ratio and the status in Congress of the one-month patch to prevent physicians who see Medicare patients from having their payments reduced.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Oros, MD 9701 Cleveland Ave Nw Ste 150, North Canton, OH 44720 Ph: (330) 913-7109 | Dr Michael J Oros, MD 9701 Cleveland Ave Nw Ste 150, North Canton, OH 44720 Ph: (330) 913-7109 |
News Archive
Obesity increases the risk of developing 10 of the most common cancers, regardless of how it is measured, according to a study of more than 400,000 adults in the UK, being presented at The European Congress on Obesity (ECO) held online this year, with central fatness (larger waist and hips) and general obesity (body mass index [BMI] and body fat percentage) associated with similar estimates of cancer risk.
Kaiser Health News staff writers Mary Agnes Carey and Julie Appleby talk with KFF's Jackie Judd about recent health policy developments, including the newly released Health and Human Services regulations dealing with the medical loss ratio and the status in Congress of the one-month patch to prevent physicians who see Medicare patients from having their payments reduced.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.
› Verified 4 days ago
Dr. Sharad H. Bhatt, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 907 S Main St, North Canton, OH 44720 Phone: 330-494-7302 Fax: 330-494-0830 |